Rigel Pharmaceuticals (RIGL) Goodwill & Intangibles (2022 - 2026)

Rigel Pharmaceuticals' Goodwill & Intangibles history runs 5 years deep, the most recent figure standing at $24.2 million for Q1 2026.

• On a quarterly basis, Goodwill & Intangibles fell 8.87% year-over-year to $24.2 million in Q1 2026; TTM through Mar 2026 was $24.2 million, a 8.87% decrease from a year earlier, with the FY2025 full-year figure at $24.7 million, down 8.68% from the prior year.
• Goodwill & Intangibles retreated to $24.2 million in Q1 2026 per RIGL's latest filing, from $24.7 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $28.9 million in Q1 2024 and bottomed at $13.9 million in Q4 2023.
• The 5-year median for Goodwill & Intangibles is $25.0 million (2025), against an average of $22.2 million.
• Across the five-year window, Goodwill & Intangibles surged 96.6% in 2024 and fell 8.87% in 2026, its largest moves.
• Year by year, Goodwill & Intangibles stood at $15.0 million in 2022, then retreated by 7.48% to $13.9 million in 2023, then soared by 95.27% to $27.1 million in 2024, then declined by 8.68% to $24.7 million in 2025, then decreased by 2.38% to $24.2 million in 2026.
• Per Business Quant, the three latest RIGL Goodwill & Intangibles figures stand at $24.2 million (Q1 2026), $24.7 million (Q4 2025), and $25.3 million (Q3 2025).